{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:10:13Z","timestamp":1771035013622,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>The increasing prevalence of heart failure (HF) has led to advancements in therapeutic strategies, including the development of new pharmacological treatments and the expansion of guideline recommendations across the spectrum of left ventricular ejection fractions. Despite these advancements, the full benefits of guideline-directed medical therapy (GDMT) are often limited by various barriers that result in incomplete implementation or suboptimal responses. For patients who cannot tolerate or only partially respond to GDMT, therapeutic options remain limited. This gap is particularly significant for those with contraindications to heart replacement therapies (HRT), such as left ventricular assist device (LVAD) or heart transplant. In light of these potential limitations, this review article proposes categorizing HF patients into four distinct phenoprofiles based on their tolerance to GDMT and candidacy for HRT. Considering these HF phenoprofiles may guide treatment decisions regarding the selection and use of novel device-based HF therapies. Furthermore, we summarize data on commercially available and emerging device-based HF therapies, evaluating their clinical utility, mechanisms of action, and selection criteria based on current evidence. Finally, we describe clinical cases across various proposed HF phenoprofiles to illustrate how these HF profiles can guide the use of novel device-based therapies to achieve clinical stability, improve GDMT tolerance, or serve as a bridge to, or be used in tandem with HRT in select patients.<\/jats:p>","DOI":"10.3389\/fcvm.2025.1419873","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:53:49Z","timestamp":1740466429000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel device therapies in heart failure: focus on patient selection"],"prefix":"10.3389","volume":"12","author":[{"given":"Amrita","family":"Balgobind","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Asemota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuuwadith","family":"Wattanachayakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Alvarez Villela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrossy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/cfr.2023.05","article-title":"Global public health burden of heart failure: an updated review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card Fail Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jchf.2024.02.020","article-title":"Contemporary American and European guidelines for heart failure management: JACC: heart failure guideline comparison","volume":"12","author":"Ostrominski","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jacc.2021.06.040","article-title":"Device therapy in chronic heart failure: JACC state-of-the-art review","volume":"78","author":"Fudim","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.xjon.2021.10.013","article-title":"The good, the bad, the ugly: optimal left ventricular assist device duration in bridge to transplantation","volume":"8","author":"Goodwin","year":"2021","journal-title":"JTCVS Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.109.934471","article-title":"Improving evidence-based care for heart failure in outpatient cardiology practices","volume":"122","author":"Fonarow","year":"2010","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e009237","DOI":"10.1161\/JAHA.118.009237","article-title":"Characteristics and treatments of patients enrolled in the CHAMP-HF registry compared with patients enrolled in the PARADIGM-HF trial","volume":"7","author":"DeVore","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jamacardio.2016.4652","article-title":"Absolute rates of heart failure, coronary heart disease, and stroke in chronic kidney disease: an analysis of 3 community-based cohort studies","volume":"2","author":"Bansal","year":"2017","journal-title":"JAMA Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/eurjhf\/hfq077","article-title":"Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population","volume":"12","author":"Hebert","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"B14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40256-024-00646-4","article-title":"Advancing guideline-directed medical therapy in heart failure: overcoming challenges and maximizing benefits","volume":"24","author":"Zhang","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.hrthm.2012.04.026","article-title":"Cardiac resynchronization therapy (CRT): clinical trials, guidelines, and target populations","volume":"9","author":"Linde","year":"2012","journal-title":"Heart Rhythm"},{"key":"B17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/ejhf.975","article-title":"Screening for heart transplantation and left ventricular assist system: results from the ScrEEning for advanced heart failure treatment (SEE-HF) study","volume":"20","author":"Lung","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"101176","DOI":"10.1016\/j.jscai.2023.101176","article-title":"Cardiac contractility modulation for heart failure: current and future directions","volume":"2","author":"Pipilas","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"101196","DOI":"10.1016\/j.jscai.2023.101196","article-title":"Reverse left ventricular remodeling with transcatheter interventions in chronic heart failure syndromes: an updated appraisal of the device landscape","volume":"2","author":"Brener","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ehf2.14575","article-title":"Enhancing myocardial function with cardiac contractility modulation: potential and challenges","volume":"11","author":"Li","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1002\/ehf2.12902","article-title":"A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life","volume":"7","author":"Giallauria","year":"2020","journal-title":"ESC Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.tcm.2021.08.001","article-title":"Magnetic resonance imaging safety in patients with cardiac implantable electronic devices","volume":"32","author":"Yang","year":"2022","journal-title":"Trends Cardiovasc Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/ejhf.3232","article-title":"Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: long-term outcomes","volume":"26","author":"Zile","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2020.05.015","article-title":"Baroreflex activation therapy in patients with heart failure with reduced ejection fraction","volume":"76","author":"Zile","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e24177","DOI":"10.1016\/j.heliyon.2024.e24177","article-title":"Baroreflex activation therapy for heart failure with reduced ejection fraction: a comprehensive systematic review and meta-analysis","volume":"10","author":"Shi","year":"2024","journal-title":"Heliyon"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12928-022-00898-4","article-title":"Mitraclip: a review of its current status and future perspectives","volume":"38","author":"Kataoka","year":"2023","journal-title":"Cardiovasc Interv Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000685","article-title":"Percutaneous tricuspid valve repair: the triclip","author":"Drogy","year":"2024","journal-title":"Cardiol Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","article-title":"Transcatheter repair for patients with tricuspid regurgitation","volume":"388","author":"Sorajja","year":"2023","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jacc.2024.05.006","article-title":"Real-world 1-year results of tricuspid edge-to-edge repair from the BRIGHT study","volume":"84","author":"Lurz","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ahj.2024.05.011","article-title":"Overview of 2024 FDA advisory panel meeting on the TriClip transcatheter tricuspid valve repair system","volume":"275","author":"Lupu","year":"2024","journal-title":"Am Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jchf.2019.11.006","article-title":"Novel devices in heart failure: BAT, atrial shunts, and phrenic nerve stimulation","volume":"8","author":"Zeitler","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jacc.2014.10.025","article-title":"Mechanisms and clinical consequences of untreated central sleep apnea in heart failure","volume":"65","author":"Costanzo","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"CD012889","DOI":"10.1002\/14651858.CD012889.pub2","article-title":"Non-invasive positive pressure ventilation for central sleep apnoea in adults","volume":"2022","author":"Pinto","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(16)30961-8","article-title":"Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial","volume":"388","author":"Constanzo","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1093\/eurheartj\/ehad346","article-title":"Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials","volume":"44","author":"Clephas","year":"2023","journal-title":"Eur Heart J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s10741-024-10426-6","article-title":"Non-invasive heart failure monitoring: leveraging smart scales and digital biomarkers to improve heart failure outcomes","volume":"29","author":"Wattanachayakul","year":"2024","journal-title":"Heart Fail Rev"},{"key":"B39","doi-asserted-by":"publisher","first-page":"12929","DOI":"10.1038\/s41598-024-63742-0","article-title":"Effectiveness of remote pulmonary artery pressure estimating in heart failure: systematic review and meta-analysis","volume":"14","author":"Urban","year":"2024","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1753944719826826","DOI":"10.1177\/1753944719826826","article-title":"An update on the CardioMEMS pulmonary artery pressure sensor","volume":"13","author":"Ayyadurai","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/ehf2.14006","article-title":"Safety and efficacy of a wireless pulmonary artery pressure sensor: primary endpoint results of the SIRONA 2 clinical trial","volume":"9","author":"Sharif","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cardfail.2022.09.006","article-title":"Rationale and design of the proactive-HF trial for managing patients with NYHA class III heart failure by using the combined Cordella pulmonary artery sensor and the Cordella heart failure system","volume":"29","author":"Guichard","year":"2023","journal-title":"J Card Fail"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jchf.2024.05.017","article-title":"Seated pulmonary artery pressure monitoring in patients with heart failure: results of the PROACTIVE-HF trial","volume":"12","author":"Guichard","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.4244\/EIJ-D-22-00544","article-title":"Transcatheter left ventriculoplasty","volume":"18","author":"Spilias","year":"2023","journal-title":"EuroIntervention"},{"key":"B45","article-title":"Study Details|Clinical Evaluation of the AccuCinch\u00ae Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study|","year":""},{"key":"B46","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.cardfail.2023.03.003","article-title":"Transcatheter left ventricular restoration in patients with heart failure","volume":"29","author":"Hamid","year":"2023","journal-title":"J Card Fail"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.36628\/ijhf.2021.0038","article-title":"Transcatheter implantation of interatrial shunt devices to lower left atrial pressure in heart failure","volume":"4","author":"J\u00f8rgensen","year":"2022","journal-title":"Int J Heart Fail"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","article-title":"Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial","volume":"399","author":"Shah","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"B49","article-title":"Study Details|Reducing Lung CongestIon Symptoms in Advanced Heart Failure|","year":""}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1419873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:53:51Z","timestamp":1740466431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1419873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":49,"alternative-id":["10.3389\/fcvm.2025.1419873"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1419873","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"article-number":"1419873"}}